AU7226798A - 9-oxime erythromycin derivatives - Google Patents

9-oxime erythromycin derivatives Download PDF

Info

Publication number: AU7226798A
Authority: AU; Australia
Prior art keywords: carbamate; deoxo; deoxy; desosaminyl; hydrazo
Prior art date: 1997-06-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU72267/98A

Other languages

English (en)

Inventor

Yong-Jin Wu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Products Inc

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-11

Filing date

1998-05-15

Publication date

1998-12-30

1998-05-15 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

1998-12-30 Publication of AU7226798A publication Critical patent/AU7226798A/en

Status Abandoned legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims description 156
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 69
125000000217 alkyl group Chemical group 0.000 claims description 62
208000015181 infectious disease Diseases 0.000 claims description 49
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
150000003839 salts Chemical class 0.000 claims description 32
125000000623 heterocyclic group Chemical group 0.000 claims description 28
238000000034 method Methods 0.000 claims description 28
125000003118 aryl group Chemical group 0.000 claims description 21
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
125000001589 carboacyl group Chemical group 0.000 claims description 19
125000001424 substituent group Chemical group 0.000 claims description 18
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 17
-1 imidazo(4,5-b)pyridin-3-yl Chemical group 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 15
229910052757 nitrogen Inorganic materials 0.000 claims description 15
125000005843 halogen group Chemical group 0.000 claims description 14
229910052760 oxygen Inorganic materials 0.000 claims description 13
229910052717 sulfur Inorganic materials 0.000 claims description 13
208000035143 Bacterial infection Diseases 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 12
208000022362 bacterial infectious disease Diseases 0.000 claims description 12
125000004093 cyano group Chemical group *C#N 0.000 claims description 12
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
125000005842 heteroatom Chemical group 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 10
241000251468 Actinopterygii Species 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
239000002798 polar solvent Substances 0.000 claims description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 claims description 2
241001024304 Mino Species 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
238000005481 NMR spectroscopy Methods 0.000 description 43
239000000243 solution Substances 0.000 description 41
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
239000007787 solid Substances 0.000 description 21
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
239000012267 brine Substances 0.000 description 18
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
239000012043 crude product Substances 0.000 description 17
239000010410 layer Substances 0.000 description 17
239000012044 organic layer Substances 0.000 description 17
229920006395 saturated elastomer Polymers 0.000 description 17
239000003120 macrolide antibiotic agent Substances 0.000 description 14
238000003556 assay Methods 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 12
239000000203 mixture Substances 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
241000283690 Bos taurus Species 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
241000606856 Pasteurella multocida Species 0.000 description 9
241000193996 Streptococcus pyogenes Species 0.000 description 9
238000012746 preparative thin layer chromatography Methods 0.000 description 9
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
238000005160 1H NMR spectroscopy Methods 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
239000002585 base Substances 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
101100119095 Enterococcus faecalis (strain ATCC 700802 / V583) ermB gene Proteins 0.000 description 7
241000191967 Staphylococcus aureus Species 0.000 description 7
241000193998 Streptococcus pneumoniae Species 0.000 description 7
230000000694 effects Effects 0.000 description 7
229940031000 streptococcus pneumoniae Drugs 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
229910004373 HOAc Inorganic materials 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
229960002626 clarithromycin Drugs 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000003818 flash chromatography Methods 0.000 description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
241001293418 Mannheimia haemolytica Species 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
125000004122 cyclic group Chemical group 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
241000606768 Haemophilus influenzae Species 0.000 description 4
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
150000001768 cations Chemical class 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
230000008261 resistance mechanism Effects 0.000 description 4
238000013207 serial dilution Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
241000193403 Clostridium Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
101150052154 MSRA1 gene Proteins 0.000 description 3
241000588655 Moraxella catarrhalis Species 0.000 description 3
241000193985 Streptococcus agalactiae Species 0.000 description 3
241000282898 Sus scrofa Species 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000008272 agar Substances 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
229940047650 haemophilus influenzae Drugs 0.000 description 3
229940041033 macrolides Drugs 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
101150021123 msrA gene Proteins 0.000 description 3
101150114366 msrA2 gene Proteins 0.000 description 3
101150006794 msrAB gene Proteins 0.000 description 3
101150109310 msrAB1 gene Proteins 0.000 description 3
101150052209 msrAB2 gene Proteins 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
244000052769 pathogen Species 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
SAHOBIBQRTZUGB-UHFFFAOYSA-N 3-quinolin-4-ylpropanal Chemical compound C1=CC=C2C(CCC=O)=CC=NC2=C1 SAHOBIBQRTZUGB-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241001148536 Bacteroides sp. Species 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241001647372 Chlamydia pneumoniae Species 0.000 description 2
241000606153 Chlamydia trachomatis Species 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
108010065152 Coagulase Proteins 0.000 description 2
241000194033 Enterococcus Species 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000590002 Helicobacter pylori Species 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000191992 Peptostreptococcus Species 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
206010062255 Soft tissue infection Diseases 0.000 description 2
241000295644 Staphylococcaceae Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
241001312524 Streptococcus viridans Species 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
238000011203 antimicrobial therapy Methods 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229940038705 chlamydia trachomatis Drugs 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
239000006071 cream Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
101150016744 ermC gene Proteins 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
229940037467 helicobacter pylori Drugs 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
208000028774 intestinal disease Diseases 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000011707 mineral Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000017066 negative regulation of growth Effects 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
239000004626 polylactic acid Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
159000000001 potassium salts Chemical class 0.000 description 2
230000002265 prevention Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
206010040872 skin infection Diseases 0.000 description 2
241000894007 species Species 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
208000019206 urinary tract infection Diseases 0.000 description 2
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
UXFKFJVEGHQOGU-UHFFFAOYSA-N 3-(4-phenylimidazol-1-yl)propanal Chemical compound O=CCCN1C=NC(C=2C=CC=CC=2)=C1 UXFKFJVEGHQOGU-UHFFFAOYSA-N 0.000 description 1
SRKDYYKNWWNIHN-UHFFFAOYSA-N 3-(4-pyridin-3-ylimidazol-1-yl)propanal Chemical compound O=CCCN1C=NC(C=2C=NC=CC=2)=C1 SRKDYYKNWWNIHN-UHFFFAOYSA-N 0.000 description 1
HRUAWKZCCFADRR-UHFFFAOYSA-N 3-(benzimidazol-1-yl)propanal Chemical compound C1=CC=C2N(CCC=O)C=NC2=C1 HRUAWKZCCFADRR-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
YPQZIFINWFTJQF-UHFFFAOYSA-N 3-imidazo[4,5-b]pyridin-3-ylpropanal Chemical compound C1=CN=C2N(CCC=O)C=NC2=C1 YPQZIFINWFTJQF-UHFFFAOYSA-N 0.000 description 1
NIOAVQYSSKOCQP-UHFFFAOYSA-N 4-hydroxynaphthalene-2-carboxylic acid Chemical class C1=CC=CC2=CC(C(=O)O)=CC(O)=C21 NIOAVQYSSKOCQP-UHFFFAOYSA-N 0.000 description 1
125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
241000606750 Actinobacillus Species 0.000 description 1
241000588986 Alcaligenes Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241001518086 Bartonella henselae Species 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000180135 Borrelia recurrentis Species 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
241001148534 Brachyspira Species 0.000 description 1
241000589875 Campylobacter jejuni Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000193468 Clostridium perfringens Species 0.000 description 1
241000224483 Coccidia Species 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
208000031973 Conjunctivitis infective Diseases 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241001518260 Corynebacterium minutissimum Species 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000008953 Cryptosporidiosis Diseases 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
241000605721 Dichelobacter nodosus Species 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
241000186394 Eubacterium Species 0.000 description 1
206010016952 Food poisoning Diseases 0.000 description 1
208000019331 Foodborne disease Diseases 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
241000605909 Fusobacterium Species 0.000 description 1
241000605952 Fusobacterium necrophorum Species 0.000 description 1
201000000628 Gas Gangrene Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000632319 Homo sapiens Septin-7 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241001148567 Lawsonia intracellularis Species 0.000 description 1
241000589242 Legionella pneumophila Species 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000186781 Listeria Species 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
208000010315 Mastoiditis Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000588622 Moraxella bovis Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100240347 Mus musculus Nectin2 gene Proteins 0.000 description 1
241000186367 Mycobacterium avium Species 0.000 description 1
241000513886 Mycobacterium avium complex (MAC) Species 0.000 description 1
241000186364 Mycobacterium intracellulare Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
241001138504 Mycoplasma bovis Species 0.000 description 1
241000202934 Mycoplasma pneumoniae Species 0.000 description 1
MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
241000605894 Porphyromonas Species 0.000 description 1
241000605861 Prevotella Species 0.000 description 1
102000055027 Protein Methyltransferases Human genes 0.000 description 1
108700040121 Protein Methyltransferases Proteins 0.000 description 1
206010037294 Puerperal pyrexia Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
102100027981 Septin-7 Human genes 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
208000019802 Sexually transmitted disease Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
241000191984 Staphylococcus haemolyticus Species 0.000 description 1
241001147691 Staphylococcus saprophyticus Species 0.000 description 1
108010015795 Streptogramin B Proteins 0.000 description 1
108010034396 Streptogramins Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000202921 Ureaplasma urealyticum Species 0.000 description 1
208000006374 Uterine Cervicitis Diseases 0.000 description 1
206010046793 Uterine inflammation Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
241000606834 [Haemophilus] ducreyi Species 0.000 description 1
NYRAVIYBIHCEGB-UHFFFAOYSA-N [K].[Ca] Chemical compound [K].[Ca] NYRAVIYBIHCEGB-UHFFFAOYSA-N 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000002814 agar dilution Methods 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
229940092524 bartonella henselae Drugs 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
206010008323 cervicitis Diseases 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
201000010251 cutis laxa Diseases 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
238000001514 detection method Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
208000010801 foot rot Diseases 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940115932 legionella pneumophila Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
229940041028 lincosamides Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
208000004396 mastitis Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
101150111763 mefA gene Proteins 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229940013390 mycoplasma pneumoniae Drugs 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
150000002923 oximes Chemical group 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
229940051027 pasteurella multocida Drugs 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
229920002721 polycyanoacrylate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
NRTYMEPCRDJMPZ-UHFFFAOYSA-N pyridine;2,2,2-trifluoroacetic acid Chemical compound C1=CC=NC=C1.OC(=O)C(F)(F)F NRTYMEPCRDJMPZ-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
229940041030 streptogramins Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
206010044008 tonsillitis Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

AU72267/98A 1997-06-11 1998-05-15 9-oxime erythromycin derivatives Abandoned AU7226798A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4934997P	1997-06-11	1997-06-11
US60049349		1997-06-11
PCT/IB1998/000741 WO1998056800A1 (en)	1997-06-11	1998-05-15	9-oxime erythromycin derivatives

Publications (1)

Publication Number	Publication Date
AU7226798A true AU7226798A (en)	1998-12-30

Family

ID=21959341

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU72267/98A Abandoned AU7226798A (en)	1997-06-11	1998-05-15	9-oxime erythromycin derivatives

Country Status (31)

Country	Link
EP (1)	EP0988308A1 (es)
JP (1)	JP2000513026A (es)
KR (1)	KR20010013660A (es)
CN (1)	CN1259135A (es)
AP (1)	AP9801253A0 (es)
AR (1)	AR012244A1 (es)
AU (1)	AU7226798A (es)
BG (1)	BG103947A (es)
BR (1)	BR9810021A (es)
CA (1)	CA2293335A1 (es)
CO (1)	CO4940506A1 (es)
CZ (1)	CZ9904388A3 (es)
EA (1)	EA199901016A1 (es)
GT (1)	GT199800074A (es)
HN (1)	HN1998000073A (es)
HR (1)	HRP980316A2 (es)
HU (1)	HUP0002252A3 (es)
ID (1)	ID24529A (es)
IL (1)	IL132767A0 (es)
IS (1)	IS5251A (es)
MA (1)	MA26505A1 (es)
NO (1)	NO996108L (es)
OA (1)	OA11225A (es)
PA (1)	PA8451801A1 (es)
PE (1)	PE79899A1 (es)
PL (1)	PL337606A1 (es)
TN (1)	TNSN98083A1 (es)
TR (1)	TR199902995T2 (es)
TW (1)	TW448174B (es)
WO (1)	WO1998056800A1 (es)
ZA (1)	ZA985018B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN1998000159A (es) *	1997-10-29	1999-02-09	Monsanto Co	Derivados de 9- amino - 3 ceto eritromicina
ATE298761T1 (de) *	1998-09-22	2005-07-15	Pfizer Prod Inc	Carbamat- und carbazatketolidantibiotika
FR2786188B1 (fr) *	1998-11-24	2002-10-31	Hoechst Marion Roussel Inc	Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
US6258785B1 (en)	1998-12-02	2001-07-10	Pfizer Inc.	Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin
EP1298138B1 (en) *	1998-12-10	2006-11-02	Pfizer Products Inc.	Carbamate and Carbazate Ketolide Antibiotics
US6284732B1 (en) *	1998-12-18	2001-09-04	Bio-Rad Laboratories, Inc.	Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
WO2000063224A2 (en) *	1999-04-16	2000-10-26	Kosan Biosciences, Inc.	Macrolide antiinfective agents
CA2373117C (en)	1999-05-24	2006-02-28	Pfizer Products Inc.	13-methyl-erythromycin derivatives
EP1181300B1 (en) *	1999-06-07	2003-09-17	Abbott Laboratories	6-o-carbamate ketolide derivatives
ID27331A (id) *	1999-09-29	2001-03-29	Pfizer Prod Inc	Pembuatan antibiotik-antibiotik ketolida karbamat
EP1114826A3 (en) *	1999-12-29	2001-10-31	Pfizer Products Inc.	Novel antibacterial and prokinetic macrolides
EP1439186A3 (en) *	1999-12-29	2004-11-03	Pfizer Products Inc.	Intermediates for novel antibacterial and prokinetic macrolides
US6946446B2 (en)	2000-02-24	2005-09-20	Abbott Laboratories	Anti-infective agents useful against multidrug-resistant strains of bacteria
US6403776B1 (en)	2000-07-05	2002-06-11	Pfizer Inc.	Synthesis of carbamate ketolide antibiotics
WO2003090761A1 (en) *	2002-04-25	2003-11-06	Abbott Laboratories	9-oxime macrolide antibacterials
US7091196B2 (en)	2002-09-26	2006-08-15	Rib-X Pharmaceuticals, Inc.	Bifunctional heterocyclic compounds and methods of making and using same
EP3738591A3 (en) *	2003-03-10	2021-03-24	Merck Sharp & Dohme Corp.	Novel antibacterial agents
WO2005085266A2 (en)	2004-02-27	2005-09-15	Rib-X Pharmaceuticals, Inc.	Macrocyclic compounds and methods of making and using the same
WO2009055557A1 (en)	2007-10-25	2009-04-30	Cempra Pharmaceuticals, Inc.	Process for the preparation of macrolide antibacterial agents
HRP20160222T1 (hr)	2008-10-24	2016-04-08	Cempra Pharmaceuticals, Inc.	Biozaštite uporabom makrolida koji sadrže triazol
US9937194B1 (en)	2009-06-12	2018-04-10	Cempra Pharmaceuticals, Inc.	Compounds and methods for treating inflammatory diseases
AU2010292010B2 (en)	2009-09-10	2016-01-07	Cempra Pharmaceuticals, Inc.	Methods for treating malaria, tuberculosis and MAC diseases
CN102146085B (zh) *	2010-02-09	2014-03-26	北京理工大学	一种9-肟醚酮内酯衍生物、制备方法及其药物组合物
NZ602544A (en)	2010-03-22	2014-11-28	Cempra Pharmaceuticals Inc	Crystalline forms of a macrolide, and uses therefor
RU2608390C2 (ru)	2010-05-20	2017-01-18	Семпра Фармасьютикалз, Инк.	Способы получения макролидов и кетолидов, и промежуточных соединений для их получения
JP6042334B2 (ja)	2010-09-10	2016-12-14	センプラファーマシューティカルズ，インコーポレイテッド	疾患治療のための水素結合形成フルオロケトライド
HK1205939A1 (en)	2012-03-27	2015-12-31	Cempra Pharmaceuticals, Inc.	Parenteral formulations for administering macrolide antibiotics
HK1217665A1 (zh)	2013-03-14	2017-01-20	森普拉制药公司	用於治療呼吸道疾病的方法及其製劑
AU2014233240B2 (en)	2013-03-15	2018-08-09	Cempra Pharmaceuticals, Inc.	Convergent processes for preparing macrolide antibacterial agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99995A (en) *	1990-11-21	1997-11-20	Roussel Uclaf	Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5527780A (en) *	1992-11-05	1996-06-18	Roussel Uclaf	Erythromycin derivatives
FR2718450B1 (fr) *	1994-04-08	1997-01-10	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.

1998
- 1998-05-15 WO PCT/IB1998/000741 patent/WO1998056800A1/en not_active Ceased
- 1998-05-15 HU HU0002252A patent/HUP0002252A3/hu unknown
- 1998-05-15 BR BR9810021-1A patent/BR9810021A/pt not_active IP Right Cessation
- 1998-05-15 CN CN98805848A patent/CN1259135A/zh active Pending
- 1998-05-15 KR KR1019997011672A patent/KR20010013660A/ko not_active Ceased
- 1998-05-15 CZ CZ19994388A patent/CZ9904388A3/cs unknown
- 1998-05-15 TR TR1999/02995T patent/TR199902995T2/xx unknown
- 1998-05-15 PL PL98337606A patent/PL337606A1/xx unknown
- 1998-05-15 EP EP98919394A patent/EP0988308A1/en not_active Withdrawn
- 1998-05-15 JP JP11501928A patent/JP2000513026A/ja active Pending
- 1998-05-15 CA CA002293335A patent/CA2293335A1/en not_active Abandoned
- 1998-05-15 AU AU72267/98A patent/AU7226798A/en not_active Abandoned
- 1998-05-15 EA EA199901016A patent/EA199901016A1/ru unknown
- 1998-05-15 ID IDW991570A patent/ID24529A/id unknown
- 1998-05-15 IL IL13276798A patent/IL132767A0/xx unknown
- 1998-05-19 HN HN1998000073A patent/HN1998000073A/es unknown
- 1998-05-21 PA PA19988451801A patent/PA8451801A1/es unknown
- 1998-06-04 AP APAP/P/1998/001253A patent/AP9801253A0/en unknown
- 1998-06-05 GT GT199800074A patent/GT199800074A/es unknown
- 1998-06-08 PE PE1998000470A patent/PE79899A1/es not_active Application Discontinuation
- 1998-06-08 TW TW087109086A patent/TW448174B/zh active
- 1998-06-09 AR ARP980102703A patent/AR012244A1/es unknown
- 1998-06-10 TN TNTNSN98083A patent/TNSN98083A1/fr unknown
- 1998-06-10 ZA ZA9805018A patent/ZA985018B/xx unknown
- 1998-06-10 MA MA25105A patent/MA26505A1/fr unknown
- 1998-06-11 CO CO98033538A patent/CO4940506A1/es unknown
- 1998-06-11 HR HR60/049,349A patent/HRP980316A2/hr not_active Application Discontinuation
1999
- 1999-11-16 IS IS5251A patent/IS5251A/is unknown
- 1999-12-03 OA OA9900269A patent/OA11225A/en unknown
- 1999-12-03 BG BG103947A patent/BG103947A/xx unknown
- 1999-12-10 NO NO996108A patent/NO996108L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EA199901016A1 (ru)	2000-06-26
HN1998000073A (es)	1999-01-08
IS5251A (is)	1999-11-16
CO4940506A1 (es)	2000-07-24
CZ9904388A3 (cs)	2002-10-16
TW448174B (en)	2001-08-01
ZA985018B (en)	1999-12-10
NO996108D0 (no)	1999-12-10
NO996108L (no)	2000-02-10
TR199902995T2 (xx)	2000-02-21
GT199800074A (es)	1999-11-27
CN1259135A (zh)	2000-07-05
TNSN98083A1 (fr)	2005-03-15
WO1998056800A1 (en)	1998-12-17
OA11225A (en)	2003-07-17
BR9810021A (pt)	2000-09-19
PE79899A1 (es)	1999-08-25
BG103947A (en)	2000-07-31
IL132767A0 (en)	2001-03-19
AR012244A1 (es)	2000-09-27
HRP980316A2 (en)	1999-04-30
AP9801253A0 (en)	1999-12-04
JP2000513026A (ja)	2000-10-03
PL337606A1 (en)	2000-08-28
CA2293335A1 (en)	1998-12-17
PA8451801A1 (es)	2000-05-24
MA26505A1 (fr)	2004-12-20
ID24529A (id)	2000-07-20
HUP0002252A2 (hu)	2000-12-28
EP0988308A1 (en)	2000-03-29
KR20010013660A (ko)	2001-02-26
HUP0002252A3 (en)	2002-01-28

Publication	Publication Date	Title
EP0988310B9 (en)	2006-03-08	4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
AU7226798A (en)	1998-12-30	9-oxime erythromycin derivatives
EP0941998B1 (en)	2004-09-01	3,6-ketal macrolide antibiotics
EP1131331B1 (en)	2004-03-03	13-membered azalides and their use as antibiotic agents
EP0895999A1 (en)	1999-02-10	C-4" substituted macrolide antibiotics
AU7228198A (en)	1998-12-30	C-4''-substituted macrolide derivatives
EP0984019B1 (en)	2004-06-02	C11 carbamates of macrolide antibacterials
US20020040007A1 (en)	2002-04-04	Novel macrolide antibiotics
EP0992509B1 (en)	2004-09-22	Novel macrolide derivatives
US6727352B2 (en)	2004-04-27	Methods of making macrolides
US6162794A (en)	2000-12-19	Erythromycin derivatives
US6248719B1 (en)	2001-06-19	Tricyclic 3-keto derivatives of 6-O-methylerthromycin
US20020025937A1 (en)	2002-02-28	9-oxime erythromycin derivatives
US6258785B1 (en)	2001-07-10	Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin
EP0952157B1 (en)	2003-06-18	9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin
EP1437360A2 (en)	2004-07-14	C11 Carbamates of macrolide antibacterials
NZ526120A (en)	2005-02-25	13-membered azalides and their use as antibiotic agents
MXPA99011494A (es)	2000-07-01	Derivados de la 9-oxima eritromicina
MXPA01005055A (es)	2001-12-04	Azalidas de 13 miembros y su uso como agentes antiobioticos
MXPA99011495A (es)	2001-05-17	Derivados de 9-desoxo-9a-homoeritromicina a c-4"sustituidos

Legal Events

Date	Code	Title	Description
2002-06-27	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted